WO2002017900A3 - Modulateurs de l'us28 - Google Patents

Modulateurs de l'us28 Download PDF

Info

Publication number
WO2002017900A3
WO2002017900A3 PCT/US2001/027363 US0127363W WO0217900A3 WO 2002017900 A3 WO2002017900 A3 WO 2002017900A3 US 0127363 W US0127363 W US 0127363W WO 0217900 A3 WO0217900 A3 WO 0217900A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokines
modulators
cytomegalovirus infections
treating cytomegalovirus
treating
Prior art date
Application number
PCT/US2001/027363
Other languages
English (en)
Other versions
WO2002017900A9 (fr
WO2002017900A2 (fr
Inventor
Thomas J Schall
Brian E Mcmaster
Daniel J Dairaghi
Original Assignee
Chemocentryx Inc
Thomas J Schall
Brian E Mcmaster
Daniel J Dairaghi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc, Thomas J Schall, Brian E Mcmaster, Daniel J Dairaghi filed Critical Chemocentryx Inc
Priority to AU2001287043A priority Critical patent/AU2001287043A1/en
Publication of WO2002017900A2 publication Critical patent/WO2002017900A2/fr
Publication of WO2002017900A9 publication Critical patent/WO2002017900A9/fr
Publication of WO2002017900A3 publication Critical patent/WO2002017900A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des essais, des compositions et des procédés de traitement permettant de moduler la liaison des chimiokines avec l'US28 à la surface des cellules.
PCT/US2001/027363 2000-08-30 2001-08-30 Modulateurs de l'us28 WO2002017900A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001287043A AU2001287043A1 (en) 2000-08-30 2001-08-30 Modulators of us28 (chemokines) for treating cytomegalovirus infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22897400P 2000-08-30 2000-08-30
US60/228,974 2000-08-30

Publications (3)

Publication Number Publication Date
WO2002017900A2 WO2002017900A2 (fr) 2002-03-07
WO2002017900A9 WO2002017900A9 (fr) 2002-06-06
WO2002017900A3 true WO2002017900A3 (fr) 2003-06-26

Family

ID=22859306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027363 WO2002017900A2 (fr) 2000-08-30 2001-08-30 Modulateurs de l'us28

Country Status (2)

Country Link
AU (1) AU2001287043A1 (fr)
WO (1) WO2002017900A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018954A2 (fr) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition de l'infection par cmv et de la dissemination de ce dernier
US20020193374A1 (en) * 2000-08-30 2002-12-19 Chemocentryx Reagents and methods for the diagnosis of CMV dissemination
WO2002062296A2 (fr) 2001-02-02 2002-08-15 Chemocentryx, Inc. Procedes et compositions utiles dans la stimulation d'une reponse immunitaire
EP1465488A4 (fr) 2001-08-30 2007-04-18 Chemocentryx Inc Arylamines utilises en tant qu'inhibiteurs de la liaison de la chemokine a us28
EP1393728A1 (fr) * 2002-08-30 2004-03-03 Vrije Universiteit Agonistes inverses agissant sur les recepteurs couplés à une protéine G codées par un virus
EP2462952A1 (fr) 2010-12-10 2012-06-13 Medizinische Universität Graz Thérapie génique du cancer utilisant des acides nucléiques codant US28

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3379729A (en) * 1965-06-22 1968-04-23 Spofa Vereinigte Pharma Werke Piperazinyldibenzothiepins
WO2000011950A1 (fr) * 1998-08-31 2000-03-09 Oregon Health Science University Inhibition de l'initiation d'une migration cellulaire au moyen d'antagonistes des recepteurs us28
WO2002018954A2 (fr) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition de l'infection par cmv et de la dissemination de ce dernier
WO2002017969A2 (fr) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Reactifs et methodes permettant de diagnostiquer la dissemination du cmv

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3379729A (en) * 1965-06-22 1968-04-23 Spofa Vereinigte Pharma Werke Piperazinyldibenzothiepins
WO2000011950A1 (fr) * 1998-08-31 2000-03-09 Oregon Health Science University Inhibition de l'initiation d'une migration cellulaire au moyen d'antagonistes des recepteurs us28
WO2002018954A2 (fr) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition de l'infection par cmv et de la dissemination de ce dernier
WO2002017969A2 (fr) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Reactifs et methodes permettant de diagnostiquer la dissemination du cmv

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEISSER P.S. ET AL: "Viral chemokine receptors and chemokines in human cytomegalovirus trafficking and interaction with the immune system: CMV chemokine receptors.", CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (2002) 269/- (203-234)., XP008009472 *
FRANCKEN, BART J. B. ET AL: "Human 5-hydroxytryptamine5A receptors activate coexpressed Gi and Go proteins in Spodoptera frugiperda 9 cells", MOLECULAR PHARMACOLOGY (2000), 57(5), 1034-1044, XP008009468 *
MCNALL, STEVEN J. ET AL: "Novel serotonin receptors in Fasciola. Characterization by studies on adenylate cyclase activation and [3H]LSD binding", BIOCHEM. PHARMACOL. (1984), 33(17), 2789-97, XP008009473 *
MICHELSON S.: "Cytomegalovirus ( CMV ) and sequestration of chemokines.", EUROPEAN CYTOKINE NETWORK, (1999) 10/2 (286-287)., XP008009470 *

Also Published As

Publication number Publication date
WO2002017900A9 (fr) 2002-06-06
AU2001287043A1 (en) 2002-03-13
WO2002017900A2 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
ATE231497T1 (de) Neue effektoren von dipeptidylpeptidase iv
AU2002365812A1 (en) Parallel computing system, method and architecture
AU2002213273A1 (en) Stenoprophiluric matrices, and methods of making and using the same
AU5435798A (en) Thin, planar heat spreader
AU6237100A (en) Low viscosity acrylate monomers, formulations containing same, and uses therefor
BR0015985B1 (pt) aplique, e, aeronave.
EP1587574A4 (fr) INHIBITEURS SELECTIFS DE 11b-HSD ET LEURS PROCEDES D'UTILISATION
AU7322200A (en) Solid sweetener compositions, liquid sweetener compositions and utilization thereof
WO2002017900A9 (fr) Modulateurs de l'us28
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2001249871A1 (en) Ether-amine based polymerization catalysts, compositions and processes using same
DK0996328T3 (da) Pollenbaseret transformationssystem, som anvender faststofmedium
AU7296200A (en) Cosmetic composition based on hardly or non-polymerised, water soluble and partly neutralised silicon organic compounds
AU2002224841A1 (en) N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds, their corresponding n-oxides and controlled radical polymerization therewith
AU4676499A (en) Treating solid, especially aluminum, surfaces
WO2000034285A3 (fr) Indenoindoles et benzofuranoindoles substitues utilises comme nouveaux elements d'ouverture de canaux potassiques
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
EP1368891B8 (fr) Modulateur iq
AU1896300A (en) Printing composition, process and printing device using the same
WO2001058954A3 (fr) Molecules trade et utilisations associees a ces dernieres
FR2798621B1 (fr) Presse chalcographique, xylographique ou similaire
AU2001234642A1 (en) Crystal structure of acps/acp complex, solution structure of b. subtilis acp, and uses thereof
WO2000000158A3 (fr) Alkylamines et leurs precurseurs, utilises comme modulateurs specifiques de la fonction des lymphocytes t gamma-delta humains
AU2001236624A1 (en) Rapid, parallel identification of cell lines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP